Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to explore the efficacy of the drug Amantadine for the treatment of freezing of gait in patients with Parkinson's Disease. The investigators hypothesize that amantadine is useful for management of freezing of gait in subjects with Parkinson's Disease.

Key facts

Study ID

NCT01652534

Run by

Northwestern University

People needed

3

Starts

2011-06-01

Expected to finish

2015-08-01

Last updated by the study team

2019-11-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with idiopathic PD as determined by UK brain bank diagnostic criteria
• H\&Y stage 2.5-3
• Presence of freezing of gait (FOG) as determined by UPDRS Part I score > 2
• Ability to walk for 2 minutes in the ON and OFF state
• Stable regimen of PD medications for 30 days prior to screening
• Ability to comply with the study procedures
• If female, be either post menopausal for at least 2 years, surgically sterilized or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception as defined in Section 6.4.10 for four weeks prior to, during and four weeks after the last dose of trial medication. For the purposes of this trial, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive.
• Willing and able to provide informed consent.

You may not qualify if…

• Presence of other co morbid conditions that can contribute to gait dysfunction (orthopedic, rheumatologic, cardiac, other)
• Presence of freezing of gait (FOG) ONLY in medications ON state
• Presence of freezing of gait (FOG) ONLY in medications OFF state
• Presence of significant cognitive dysfunction as determined by Montreal Cognitive Assessment (MoCA) <20
• Presence of clinically significant depression as determined by geriatric depression scale (GDS)- 15>5
• Presence of clinically significant hallucinations
• Inability to sign informed consent
• Participation in the physical therapy aimed at management of PD for the duration of the study (PT for orthopedic issues will be allowed)
• Contraindications for use of Amantadine ( prior history of allergic reaction, history of known renal insufficiency with Cr > 2)
• If female, be pregnant or lactating

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.